Medtronic extends Activa therapy to dystonia:
This article was originally published in Clinica
Executive Summary
Medtronic has gained US approval to expand the use of its Activa brain stimulation technology to the treatment of a neurological movement disorder called dystonia. The device, approved under the agency's Humanitarian Device Exemption regulations for treating the most severe and disabling forms of the condition, is already cleared for treating symptoms of advanced Parkinson's disease and essential tremor. Medtronic says that every year in the US around 2,400 patients are diagnosed with forms of dystonia that may be treated with the Activa device. European approval for the dystonia indication is expected to come later this year.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.